Journal profile · Biochemistry, Genetics and Molecular Biology-Molecular Medicine
Molecular Biomedicine
ISSN 2662-8651 · Springer · Switzerland
Molecular Biomedicine: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 13 (journal website); fully open access; APC about USD 2,990; median 221 days to acceptance (117 articles, last 24 months); 153 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Molecular Biomedicine is published by Springer and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Immune cells in cancer, Epigenetics and DNA Methylation and Ferroptosis and cancer prognosis, together about 21% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Molecular Biomedicine is a peer-reviewed, online open access, multidisciplinary journal that publishes the pioneer works of biomedicine, emphasizing on pathogenic mechanism and innovative techniques for diagnosis and therapy. This journal has an international authorship and a broad scope in basic, translational and clinical research including but not limited to:Epigenetics, genomics and proteomicsGene editingRNA biologySignal transductionStructural biologyEarly diagnosis and biomarkers of diseaseGene therapy, cell therapy and immunotherapyTargeted therapy by small moleculesMolecular imagingArtificial intelligence in medicineRegenerative medicineExcept where otherwise stated, manuscripts are single-blind peer reviewed. Papers will be sent to review if the Editor-in-Chief determines that the paper meets the appropriate quality and relevance requirements.
From the journal's Aims & Scope
Research area (LetPub): Biochemistry, Genetics and Molecular Biology-Molecular Medicine
Editor-in-chief Arnold DriessenPublisher website
Editorial board by country: 9 in mainland China (about 20%); most named United States 14, Mainland China 9, Israel 4, Japan 3, Australia 3 (46 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Immune cells in cancerImmunology and Microbiology7.9%
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology6.9%
- Ferroptosis and cancer prognosisMedicine6.2%
- SARS-CoV-2 and COVID-19 ResearchMedicine6%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology6%
- Cancer Immunotherapy and BiomarkersMedicine4.9%
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology4.6%
- Cancer Cells and MetastasisMedicine4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Biochemistry & Molecular Biology | Zone 2 |
| Minor | Cell Biology | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 2 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Biochemistry & Molecular Biology | Zone 2 |
| Minor | Cell Biology | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Biochemistry & Molecular Biology | Zone 4 |
| Minor | Cell Biology | Zone 4 |
| Minor | Medicine, Research & Experimental | Zone 4 |
Top journal: noReview journal: no
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINECASPublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 13Publisher website ·
- 5-year impact factor (publisher) 2025
- 11.8Publisher website ·
- CiteScore 2026-06
- 11.7LetPub ·
- SJR 2026-06
- 2.99LetPub ·
- SNIP 2026-06
- 2.06LetPub ·
- h-index
- 55OpenAlex ·
- i10-index
- 206OpenAlex ·
- 2-year mean citedness
- 11.4OpenAlex ·
- Self-citation rate
- 2.3%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 128LetPub ·
- Downloads per year (publisher) 2025
- 941,800Publisher website ·
Articles by year OpenAlex count · 574 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 189 | 189 | 419 |
| 2025 | 153 | 153 | 2,564 |
| 2024 | 74 | 74 | 1,758 |
| 2023 | 50 | 50 | 1,588 |
| 2022 | 48 | 48 | 2,279 |
| 2021 | 41 | 41 | 1,386 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
221 daysMedian, submission to acceptance · P25–P75 172 days – 274 days
- Acceptance to online
- median 15 days (117 articles)
- Submission to online
- median 239 days
- Sample
- 117 articles with submission and acceptance dates (366 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 10 weeksLetPub ·
- Submission to first decision
- 15 daysPublisher website ·
- Submission to publication (journal-reported)
- about 10 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 2,490 / USD 2,990 / GBP 2,190 | Yes | CC BY | |
| OpenAlex | USD 2,590 / EUR 2,190 / GBP 1,890 | — | — | |
| LetPub | GBP 1,790 / USD 2,490 / EUR 2,090 | Yes | — | |
| Publisher website | GBP 2,190 / USD 2,990 / EUR 2,490 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare4 items from the author guidelines
- Abstract
- 150–250 words
- Keywords
- ≥ 4
- Manuscript length
- ≤ 6,000 words
- Reference style
- Numbered, in order of citation
Article types accepted8, with length limits
- consensusConsensus Consensus papers should contain an unstructured Abstract with up to 250 words.Length not stated
- letterResearch Articles describe original research, and should be 3000-6000 words (excluding the abstract, tables, figure legends and references) and contain no more …Length not stated
- original researchResearch Articles describe original research, and should be 3000-6000 words (excluding the abstract, tables, figure legends and references) and contain no more …Length not stated
- research articleResearch Articles describe original research, and should be 3000-6000 words (excluding the abstract, tables, figure legends and references) and contain no more …main text ≤ 6,000 words
- research articlesResearch Articles describe original research, and should be 3000-6000 words (excluding the abstract, tables, figure legends and references) and contain no more …Length not stated
- research highlightResearch Highlight Research Highlights discuss the main advances made by the paper as well as putting the finds of the study into the proper context of the fiel…Length not stated
- research paperResearch Articles describe original research, and should be 3000-6000 words (excluding the abstract, tables, figure legends and references) and contain no more …Length not stated
- reviewResearch Articles describe original research, and should be 3000-6000 words (excluding the abstract, tables, figure legends and references) and contain no more …Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, License & copyright, Open access, Peer review
- AI use Generative AI Images
Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein. Back to top
Source ↗Publisher website ·- Authorship Authorship principles
These guidelines describe authorship principles and good authorship practices to which prospective authors should adhere to. Authorship clarified The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before th…
Source ↗Publisher website ·- Conflicts of interest Competing Interests
Authors are requested to disclose interests that are directly or indirectly related to the work submitted for publication. Interests within the last 3 years of beginning the work (conducting the research and preparing the work for submission) should be reported. Interests outside the 3-year time frame must be disclosed if they could reasonably be perceived as influencing the submitted work. Disclo…
Source ↗Publisher website ·- Data availability Data availability statements
Data availability statement required Model summary
All original research must include a data availability statement. This statement should explain how to access data supporting the results and analysis in the article, including links/citations to publicly archived datasets analysed or generated during the study. Please see our full policy here. If it is not possible to share research data publicly, for instance when individual privacy could be com…
Source ↗Publisher website ·- Publication ethics Compliance with Ethical Standards
To ensure objectivity and transparency in research and to ensure that accepted principles of ethical and professional conduct have been followed, authors should include information regarding sources of funding, potential conflicts of interest (financial or non-financial), informed consent if the research involved human participants, and a statement on welfare of animals if the research involved an…
Source ↗Publisher website ·- License & copyright Copyright
Articles in Springer Nature open access journals do not require transfer of copyright as the copyright remains with the author. Details of the OA licences offered to authors can be found on the individual journal website, in the journal's How to publish with us guide. Back to top
Source ↗Publisher website ·- Open access Open access publishing
Copyright remains with the author Model summary
To find out more about publishing your work Open Access in Molecular Biomedicine, including information on fees, funding and licences, visit our Open access publishing page. Back to top
Source ↗Publisher website ·- Peer review Single-blind peer review
Single-blind peer review Model summary
This journal follows a single-blind reviewing procedure. This journal also publishes special/guest-edited issues. The peer review process for these articles is the same as the peer review process of the journal in general. Additionally, if a guest editor authors an article in their issue/collection, they will not handle the peer review process. Back to top
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer
- Country or region
- Switzerland
- Language
- English
- ISSN
- 2662-8651
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Molecular Biomedicine
What CAS zone is Molecular Biomedicine in?
In the 2025 upgraded edition of the CAS Journal Ranking, Molecular Biomedicine is in Zone 2 of Medicine, and in Zone 2 of the minor category Biochemistry & Molecular Biology / Cell Biology / Medicine, Research & Experimental. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Molecular Biomedicine?
The journal's website gives an impact factor of 13 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 11.7, h-index 55.
How long does peer review take at Molecular Biomedicine?
Based on the dates recorded on 117 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 221 days (interquartile range 172–274 days); authors report an average review time of about 10 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Molecular Biomedicine?
According to the journal's author guidelines: Abstract: 150–250 words; Keywords: ≥ 4; Manuscript length: ≤ 6,000 words; Reference style: Numbered, in order of citation. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Molecular Biomedicine based?
Of the 46 board members whose country the journal's board page names, 9 (about 20%) are in mainland China; the countries named most often are United States (14), Mainland China (9) and Israel (4). Counted from the institutions listed on the board page; for reference only.
Which databases index Molecular Biomedicine?
According to LetPub and DOAJ records, Molecular Biomedicine is indexed in ESCI, Scopus and DOAJ. The journal's website also lists MEDLINE and CAS; that list has not been checked against each database.
Is Molecular Biomedicine open access, and what is the APC?
Molecular Biomedicine is a fully open-access journal. APC about USD 2,990.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .